Wayne Goodman

Wayne Goodman, MD
Fields Psychiatry, Neurology
Institutions Icahn School of Medicine at Mount Sinai
Alma mater Boston University School of Medicine, Yale School of Medicine
Known for

Obsessive Compulsive Disorder, Yale-Brown Obsessive Compulsive Scale

International OCD Foundation, Deep Brain Stimulation

Wayne Goodman, MD, is an American psychiatrist and researcher who specializes in Obsessive-Compulsive Disorder (OCD). He is the principal developer, along with his colleagues, of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), which is considered to be the gold standard for assessing OCD.[1]

Goodman has served as Chairman of the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai since July 2009. During his tenure, the Department rose to be among the top ten in the nation in research funding from the National Institutes of Health.[2][3]

Biography

Prior to joining Mount Sinai, Goodman served as Director of the Division of Adult Translational Research and Treatment Development at the National Institute of Mental Health from 2007-2009. He also served as Chairman of the Department of Psychiatry at the University of Florida in Gainesville for nine years.

A native of New York City, Goodman attended the Bronx High School of Science and graduated from Columbia University with a degree in Electrical Engineering. He received his medical degree from Boston University School of Medicine and completed his internship, residency, and research fellowship at Yale School of Medicine.[4]

Major accomplishments in OCD

Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

In 1985, Dr. Goodman founded and served as Chief of the OCD Clinic at Yale University. During this time, along with his colleagues Lawrence Price and Steven Rasmussen, he developed the Y-BOCS, which is widely used in research and clinical practice to determine the severity of OCD and to monitor improvement during treatment. It has since been translated into numerous languages.[1]

Goodman and his colleagues have also developed the Yale-Brown Obsessive-Compulsive Scale—Second Edition (Y-BOCS-II) in an effort to modify the original scale.[5] Other rating scales developed by Goodman and his colleagues include: the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS),[6] Florida Obsessive Compulsive Inventory (FOCI),[7] the Children's Florida Obsessive Compulsive Inventory (C-FOCI),[8] Level 2—Repetitive Thoughts and Behaviors (Cross-cutting symptom measure used in the DSM-5),[9] and the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP).[10]

Selective serotonin reuptake inhibitors

Goodman was one of the first investigators to test and establish the efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs) in OCD and show their comparative advantage over other antidepressant medications.[11] He also developed the use of adjunctive antipsychotic medications in SSRI-resistant OCD and found that patients with comorbid tic disorders are most likely to respond to this combination.[12]

International OCD Foundation

In 1986, Goodman co-founded the nonprofit OCD Foundation (now named the International OCD Foundation). While on faculty at Yale University, he had the idea to bring together a group of dedicated individuals with OCD who were participating in research studies for a self-help group. They later expanded and started a foundation to help reach a wider audience and educate the public about OCD and treatment options.[13] He served as Chair of its Scientific Advisory Board for the first ten years. Goodman received the Lifetime Career Achievement Award from the International OCD Foundation in 2012.[14]

Deep brain stimulation

Goodman conducts research in the use of Deep Brain Stimulation (DBS) for treatment-resistant psychiatric disorders. He has published on the use of DBS for intractable OCD.[15][16]

Service with the Food and Drug Administration

Goodman served as chair of the FDA Psychopharmacology Drug Advisory Committee (PDAC) from 2004-2008. During that time period, the FDA deliberated and eventually decided to require a Black Box warning on suicidality for all antidepressant drugs.[17] Goodman voted in favor of the Black Box warning for the pediatric population in 2004.[18] Two years later, he voted that the warning be extended up to age 24. He has also served on the FDA Neurological Devices Advisory Committee.[19]

References

  1. 1 2 Goodman, W.K; Price, L.H; Rasmussen, S.A; et al. (1989). "The Yale–Brown Obsessive–Compulsive Scale. I. Development, use, and reliability". Arch Gen Psychiatry 46: 1006–1011. doi:10.1001/archpsyc.1989.01810110048007. PMID 2684084.
  2. ↑ "Wayne K. Goodman, MD, Renowned Expert on Obsessive Compulsive Disorder, Joins Mount Sinai as Chair of Psychiatry". PRWeb. 4 May 2009.
  3. ↑ "Ranking Tables of National Institutes of Health (NIH) Award Data 2014". brimr.org.
  4. ↑ "Wayne Goodman - The Mount Sinai Hospital". The Mount Sinai Hospital.
  5. ↑ Storch EA1, Rasmussen SA; Price, LH; Larson, MJ; Murphy, TK; Goodman, WK (Jun 2010). "Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition". Psychol Assess 22 (2): 223–32. doi:10.1037/a0018492. PMID 20528050.
  6. ↑ Scahill, L; Riddle, MA; McSwiggin-Hardin, M; Ort, SI; King, RA; Goodman, WK; Cicchetti, D; Leckman, JF (Jun 1997). "Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity". J Am Acad Child Adolesc Psychiatry 36 (6): 844–52. doi:10.1097/00004583-199706000-00023. PMID 9183141.
  7. ↑ Storch, EA; Kaufman, DA; Bagner, D; Merlo, LJ; Shapira, NA; Geffken, GR; Murphy, TK; Goodman, WK (Sep 2007). "Florida Obsessive-Compulsive Inventory: development, reliability, and validity". J Clin Psychol 63 (9): 851–9. doi:10.1002/jclp.20382. PMID 17674398.
  8. ↑ Storch EA1, Khanna M; Merlo, LJ; Loew, BA; Franklin, M; Reid, JM; Goodman, WK; Murphy, TK (Sep 2009). "Children's Florida Obsessive Compulsive Inventory: psychometric properties and feasibility of a self-report measure of obsessive-compulsive symptoms in youth". Child Psychiatry Hum Dev. 40 (3): 467–83. doi:10.1007/s10578-009-0138-9. PMID 19326209.
  9. ↑ American Psychiatric Association.(2013).Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC.
  10. ↑ Bussing R, Murphy TK, Storch EA, McNamara JP, Reid AM, Garvan CW, Goodman WK (2013). "Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD". Psychiatry Res 205: 253–61. doi:10.1016/j.psychres.2012.09.019. PMC 3540123. PMID 23031804.
  11. ↑ Goodman, WK; Price, LH; Delgado, PL; Palumbo, J; Krystal, JH; Nagy, LM; Rasmussen, SA; Heninger, GR; Charney, DS (Jun 1990). "Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.". Arch Gen Psychiatry 47: 577–85. doi:10.1001/archpsyc.1990.01810180077011. PMID 2112374.
  12. ↑ McDougle CJ1, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr;51(4):302-8. PBMI 8161290
  13. ↑ "History of the Clinic". yale.edu.
  14. ↑ "Wayne Goodman, MD, Receives Career Achievement Award from International OCD Foundation". The Mount Sinai Hospital.
  15. ↑ Goodman, WK; Alterman, RL (2012). "Deep brain stimulation for intractable psychiatric disorders". Annu Rev Med. 63: 511–24. doi:10.1146/annurev-med-052209-100401. PMID 22034866.
  16. ↑ Goodman, WK; Foote, KD; Greenberg, BD; Ricciuti, N; Bauer, R; Ward, H; Shapira, NA; Wu, SS; Hill, CL; Rasmussen, SA; Okun, MS (Mar 2010). "Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design". Biol Psychiatry 67 (6): 535–42. doi:10.1016/j.biopsych.2009.11.028. PMID 20116047.
  17. ↑ Goodman WK1, Murphy TK; Storch, EA (Mar 2007). "Risk of adverse behavioral effects with pediatric use of antidepressants". Psychopharmacology (Berl). 191 (1): 87–96. doi:10.1007/s00213-006-0642-6. PMID 17180618.
  18. ↑ "Food and Drug Administration". fda.gov.
  19. ↑ http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM394254.pdf
This article is issued from Wikipedia - version of the Friday, February 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.